Carregant...
Pharmacodynamics of natalizumab extended interval dosing in MS
OBJECTIVE: To determine if the concentration and saturation of natalizumab (NTZ) administration at extended interval dosing (EID; every 5–8 weeks) over 18 months is able to be maintained in the range considered adequate to sustain the clinical efficacy of NTZ. METHODS: In a cross-sectional assessmen...
Guardat en:
| Publicat a: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Lippincott Williams & Wilkins
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7057061/ https://ncbi.nlm.nih.gov/pubmed/32019876 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000672 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|